Clinical trials · New York, NY
Metastatic Renal Cell Carcinoma clinical trials in New York
We’re tracking 62 recruiting metastatic renal cell carcinoma studies with a site in or near New York — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
New York, New YorkAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
New York, New YorkAges 18 years+ - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
New York, New YorkAges 18 years+ - NCT07195682RecruitingPhase 1
Study of an experimental drug for advanced kidney cancer
This trial tests a new drug (BMS-986506) for people with advanced kidney cancer (clear cell renal cell carcinoma). It aims to see if the drug is safe and effective. Depending on the part of the study, participants may have had prior treatments or be newly diagnosed.
New York, New YorkAges 18 years+ - NCT07227415RecruitingPhase 1/Phase 2
Study of a new drug for advanced kidney cancer
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
New York, New YorkAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
New York, New YorkAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
New York, New YorkAges 18 years+ - NCT06835972RecruitingPhase 1/Phase 2
Abemaciclib and cabozantinib for advanced kidney cancer
This trial tests a new combination of two oral drugs (abemaciclib and cabozantinib) for people with advanced kidney cancer (clear cell type) who have already tried at least two other treatments, including an immunotherapy and a targeted therapy, but their cancer kept growing. The goal is to see if this combination can shrink tumors or slow the cancer.
New York, New YorkAges 18 years+ - NCT06863311RecruitingPhase 2
Trial of zanzalintinib with immunotherapy for advanced kidney cancer
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
New York, New YorkAges 18 years+ - NCT04977453RecruitingPhase 1/Phase 2
Study drug GI-101 alone or with immune or blood-pressure meds
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT05873686RecruitingPhase 1
Study of NXP900 for advanced solid tumors
This trial tests a new drug called NXP900 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: one for any advanced solid tumor and another for tumors with specific genetic changes.
New York, New YorkAges 18 years+ - NCT05440708RecruitingPhase 1/Phase 2
Study drug for advanced liver cancer that cannot be removed
This trial tests TTI-101, by itself and with other cancer medicines, for liver cancer that is advanced and cannot be removed by surgery. It aims to see whether the treatment can slow the cancer down and improve outcomes.
New York, New YorkAges 18 years+ - NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
New York, New YorkAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
New York, New YorkAges 18 years+ - NCT07179770RecruitingPhase 1
Belzutifan and imaging in advanced kidney cancer
This trial tests a new drug called belzutifan combined with a special imaging agent (89Zr-DFO-girentuximab) to see how they affect PET scans in people with advanced clear cell kidney cancer. It may help doctors better understand the cancer and guide treatment.
New York, New YorkAges 18 years+ - NCT06699602RecruitingPhase 2
Immunotherapy before kidney surgery for high-risk kidney cancer
This trial tests a combination of two immunotherapy drugs (cemiplimab and fianlimab) given before surgery for high-risk kidney cancer that has not spread. The goal is to see if the drugs can help reduce the risk of the cancer coming back or spreading in the future.
New York, New YorkAges 18 years+ - NCT07300241RecruitingPhase 1
Study of NEO-811 for advanced kidney cancer
This trial tests a new drug called NEO-811 for people with advanced clear cell kidney cancer that has spread and can't be removed with surgery. The goal is to see if it helps when other treatments have stopped working or aren't an option.
New York, New YorkAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
New York, New YorkAges 18–80 - NCT05307939RecruitingPhase 2
Using tumor DNA tests to time treatment for HPV throat cancer
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
New York, New YorkAges 18 years+ - NCT06234605RecruitingPhase 1
Study of a new combination for advanced kidney cancer
This trial tests an experimental drug (HC-7366) combined with an approved targeted therapy (belzutifan) for people with advanced kidney cancer. It aims to see if the combination is safe and works better than either drug alone.
New York, New YorkAges 18 years+ - NCT07195734RecruitingPhase 2
Adding chemo or immunotherapy before surgery for advanced head and neck cancer
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
Jersey City, New JerseyAges 18 years+ - NCT05366829RecruitingPhase 2
Tislelizumab after liver tumor radiation to reduce cancer return
This Phase 2 trial tests tislelizumab (an immunotherapy medicine) given after liver-directed radiation to help prevent hepatocellular carcinoma (liver cancer) from coming back or spreading. It may help by boosting the immune system to better control remaining cancer.
The Bronx, New YorkAges 18 years+
Hear when a new Metastatic Renal Cell Carcinoma trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Metastatic Renal Cell Carcinoma trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting metastatic renal cell carcinoma studies listed above.
- Memorial Sloan Kettering Cancer Center · 13 studies
- Memorial Sloan Kettering Bergen · 6 studies
- Memorial Sloan Kettering Monmouth · 6 studies
- Memorial Sloan Kettering Nassau · 6 studies
- Memorial Sloan Kettering Basking Ridge · 5 studies
- Memorial Sloan Kettering Commack · 5 studies
- Memorial Sloan Kettering Cancer Center - Westchester · 4 studies
- NYU Langone Health · 3 studies
What taking part in a metastatic renal cell carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic renal cell carcinoma studies in New York.
Common questions
- Are there metastatic renal cell carcinoma clinical trials near New York?
- Yes. We're currently tracking 62 recruiting metastatic renal cell carcinoma studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic renal cell carcinoma study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic renal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic renal cell carcinoma studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.